Recent 8-K filings for TEM

• July 30, 2026, 4:01 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Tempus AI Q2 revenue $382.5M (+22% YoY); raises FY2026 guidance to $1.595-1.605B

  Revenue $382.5M, up 22% YoY; GAAP net income $5.6M vs loss $42.8M in Q2 2025.

• July 20, 2026, 5:15 PM ET M&A materiality 0.85 neutral item 1.01item 9.01

  Tempus AI to acquire Personalis for $16.25/share; stock/cash mix; exchange ratio tied to TEM price

  Per share consideration: $16.25 cash or stock based on exchange ratio; Tempus may elect cash for up to 50% of shares.

• July 20, 2026, 9:03 AM ET M&A materiality 0.80 positive item 7.01item 9.01

  Tempus AI to acquire Personalis for $1.5B, adding MRD technology to precision oncology platform

  Total enterprise value of $1.5B net of Tempus' existing stake; $16.25 per share in stock, with Tempus option to pay up to 50% cash.

• May 22, 2026, 4:01 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

  Tempus AI shareholders elect all nine directors, ratify PwC, approve triennial say-on-pay

  All nine director nominees elected; highest votes for Eric D. Belcher with 234,038,276 for, 1,072,748 withheld.

• May 12, 2026, 7:18 PM ET debt materiality 0.75 positive item 1.01item 1.02item 2.03item 3.02item 8.01item 9.01 ◈ Material Agreements

  Tempus AI closes $460M 0% convertible notes due 2032; repays $307.7M credit facility

  Issued $460M aggregate principal of 0.00% Convertible Senior Notes due 2032, conversion price ~$69.26/share.

• May 5, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Tempus AI Q1 revenue $348M (+36% YoY); raises FY2026 guidance to $1.59-1.60B

  Revenue $348.1M, +36% YoY; Diagnostics $261.1M (+34.7%), Data & Apps $87.0M (+40.5%).

• February 24, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Tempus AI Q4 revenue $367.2M (+83% YoY); guides FY26 revenue ~$1.59B, adj. EBITDA ~$65M

  Q4 revenue $367.2M (+83% YoY, 33.5% organic); Diagnostics $266.9M (+121.6%) with Oncology volume +29%, Hereditary +23%.

• January 12, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Tempus AI reports preliminary FY2025 revenue ~$1.27B (+83% YoY); TCV exceeds $1.1B

  FY2025 revenue ~$1.27B (+83% YoY); diagnostics ~$955M (+111%), data/apps ~$316M (+31%).

• November 4, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Tempus AI Q3 revenue $334M (+84.7% YoY); turns positive adjusted EBITDA; raises FY guidance

  Revenue $334.2M, +84.7% YoY; gross profit $209.9M, +98.4% YoY.

• August 27, 2025, 7:59 PM ET other materiality 0.10 neutral item 8.01item 9.01

  Tempus AI files prospectus supplement for resale of 1,268,033 shares by selling stockholders

  Filed prospectus supplement on August 27, 2025, covering resale of 1,268,033 Class A common shares.

• August 8, 2025, 7:59 PM ET earnings materiality 0.50 positive item 2.02item 7.01item 9.01

  Tempus AI Q2 rev $315M (+90% YoY); raises FY25 guidance to $1.26B, adj EBITDA $5M

  Revenue $314.6M (+89.6% YoY); genomics up 115% to $241.8M; data/services +35.7% to $72.8M.

• July 3, 2025, 7:59 PM ET debt materiality 0.80 positive item 1.01item 2.03item 3.02item 8.01item 9.01

  Tempus AI closes $750M 0.75% convertible note offering, repays $274.7M term loans

  Issued $750M aggregate principal of 0.75% Convertible Senior Notes due July 15, 2030, including full over-allotment.

• May 23, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Tempus AI shareholders approve reincorporation from Delaware to Nevada at annual meeting

  Reincorporation approved with 229,810,726 votes for, 13,226,368 against, 44,166 abstentions.

• May 6, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Tempus Q1 revenue up 75.4% to $255.7M; raises FY2025 revenue guidance to $1.25B

  Revenue $255.7M (+75.4% YoY); gross profit $155.2M (+99.8% YoY) with margin improvement in Genomics and Data & Services.

• April 23, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01

  Tempus AI inks deals with AstraZeneca, Pathos for $200M data licensing, $35M fee for oncology AI model

  AstraZeneca pays Tempus $35M under MSA for foundational multimodal oncology model developed by Pathos using Tempus de-identified data.

• February 24, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Tempus AI Q4 revenue $200.7M (+35.8% YoY); guides FY25 revenue ~$1.24B, Adj. EBITDA ~$5M

  Q4 revenue $200.7M (+35.8% YoY); Genomics $120.4M, Data $80.2M. Gross profit $122.1M (+49.7%).

• February 3, 2025, 6:59 PM ET debt materiality 0.70 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings ×2

  Tempus AI borrows $300M to fund Ambry Genetics acquisition – term loans and revolver

  Borrowed $200M in incremental term loans and $100M in revolving loans on Feb 3, 2025.

• January 13, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Tempus AI Q4 2024 revenue ~$200M (+35% YoY); full year ~$693M (+30%)

  Preliminary Q4 2024 revenue ~$200M, up ~35% YoY; full-year revenue ~$693M, up ~30%.

• November 5, 2024, 6:59 PM ET M&A materiality 0.85 neutral item 1.01item 3.02item 9.01

  Tempus AI to acquire Ambry Genetics for $375M cash plus ~4.84M shares

  Acquisition of Ambry Genetics (genetic testing) for $375M cash + 4,843,136 TEM shares valued at ~$46.46/share avg VWAP.

• November 4, 2024, 6:59 PM ET M&A materiality 0.85 positive item 2.02item 7.01item 9.01

  Tempus AI Q3 revenue $180.9M (+33% YoY), net loss $75.8M, agrees to buy Ambry Genetics for $600M

  Q3 revenue $180.9M (+33% YoY); net loss $75.8M (incl. $22.2M stock comp); Adj EBITDA -$21.8M (improved $14.4M YoY).

• September 6, 2024, 7:59 PM ET other material materiality 0.55 neutral item 8.01

  Tempus AI defers settlement of 4.47M CEO RSUs to Jan-Mar 2025 with sell-to-cover expected

  Compensation Committee deferred settlement of ~4,469,400 RSUs held by CEO Eric Lefkofsky.

• August 20, 2024, 7:59 PM ET other material materiality 0.70 neutral item 8.01

  Tempus AI invests $17.7M in Personalis, exercises warrants for 9.2M shares

  Purchased 3,500,000 Personalis shares at $5.07/share, aggregate $17,745,000.

• August 6, 2024, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 7.01item 9.01

  Tempus Q2 revenue $166M, up 25% YoY; guides FY2024 revenue ~$700M

  Revenue $166.0M (+25% YoY); data licensing grew 40% YoY; genomics revenue $112.3M (+22.2%).

• June 17, 2024, 7:59 PM ET other material materiality 0.50 neutral item 5.03item 9.01

  Tempus AI files amended charter and bylaws effective upon IPO closing on June 17, 2024

  IPO of Tempus AI closed on June 17, 2024; shares trade on Nasdaq under 'TEM'.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.80 · Most common event earnings

14 positive 0 negative 10 neutral

source · TEM on sec.gov